HCPCS Level II code J9214 denotes the injection of recombinant interferon alfa-2b, measured per 1 million units. This drug-class billing code matters nationally because interferon alfa-2b is used in oncology and certain antiviral or immunologic treatments where accurate drug-unit reporting affects clinical documentation, drug inventory management, and payer adjudication. The code is relevant across governmental and commercial payers given its use in hospital outpatient departments, ambulatory infusion centers, and physician offices.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9214 represents clinically and operationally, guidance on where services are typically delivered, and an outline of the payer types that commonly reimburse this injectable biologic. The publication summarizes benchmarking and coverage contexts, highlights coding considerations tied to unit-based billing, and notes typical billing modifiers and settings where this code appears.

This summary is intended for a national audience of billing professionals, practice managers, and policy analysts who need a clear reference on the clinical meaning, service contexts, and payer landscape for HCPCS Level II code J9214. Data not available in the input are identified where applicable.